AlphaFlo canine allograft has been released to market
The product is an alternative to current canine care modalities.
Equus Innovations—a manufacturer of veterinary regenerative products—in collaboration with AlphaLogix, LLC (Argyle, Texas) has announced the successful market release of a new canine allograft, AlphaFlo.
"The release of AlphaFlo by AlphaLogix is another exciting regenerative solution for veterinary patients. We are privileged to be partners in advancing these innovative allograft products,” said Grant D. Senner, MD, DABRM and Equus Innovations' CEO, in a company release.1
According to the release,1 AlphaFlo is a liquid, acellular, canine amniotic tissue allograft consisting of amnion, intended to support and protect tissues. It is cryopreserved and provided frozen in 3 volumes. Amniotic tissues have reported anti-inflammatory, anti-microbial, anti-fibrotic, and regenerative properties, making them ideal for veterinary applications.
Tissues are obtained from healthy dogs during live birth by licensed veterinarians with safe recovery techniques and sterile equipment without danger to the animals.1 Allografts are subject to rigorous United States Pharmacopeia testing before release for implantation.
Additionally, Equus Innovations is the manufacturer of RenoVō equine allograft, distributed by Equine Amnio Solutions, LLC (EAS).
Reference
AlphaLogix announces market release of AlphaFlo® canine allograft. News release. Equus Innovations. March 31, 2022. Accessed March 31, 2022. https://www.prnewswire.com/news-releases/alphalogix-announces-market-release-of-alphaflo-canine-allograft-301514097.html
